コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 by tetrahydrolipstatin (THL, an inhibitor of lipoprotein lipase).
2 id metabolism, e.g. serum protein Igfbp1 and lipoprotein lipase.
3 onectin, perilipin, fatty acid synthase, and lipoprotein lipase.
4 hat was a poorer substrate for hydrolysis by lipoprotein lipase.
5 that shed adipocyte syndecans associate with lipoprotein lipase.
6 via their ability to inhibit the activity of lipoprotein lipase.
7 hed syndecan ectodomain can stabilize active lipoprotein lipase.
8 ruses expressing the mutant apoA-I and human lipoprotein lipase.
9 th a recombinant adenovirus expressing human lipoprotein lipase.
10 triglycerides, whose activity is enhanced by lipoprotein lipase.
11 ide levels and no inhibition of lipolysis by lipoprotein lipase.
12 p-regulation of those for hepatic lipase and lipoprotein lipase.
13 uscle cell-derived matrix in the presence of lipoprotein lipase.
14 e proliferator-activated receptor gamma2 and lipoprotein lipase.
15 egraded atherogenic lipoproteins enriched in lipoprotein lipase.
16 iferator-activated receptor gamma2, aP2, and lipoprotein lipase.
17 ngs through the actions of these hormones on lipoprotein lipase.
18 at are sensitive to the action of the enzyme lipoprotein lipase.
19 PTL4) has been identified as an inhibitor of lipoprotein lipase.
20 lipoprotein binding protein1's other ligand, lipoprotein lipase.
21 retention in Bruch's membrane is mediated by lipoprotein lipase.
22 3 (ANGPTL3) inhibits lipolysis by binding to lipoprotein lipases.
23 lation of lipid is due to an upregulation of lipoprotein lipase (20-fold) and Cd36 (167-fold) and dow
27 e impaired clearance occurred despite normal lipoprotein lipase activity and likely reflected feedbac
29 treatment did not significantly alter basal lipoprotein lipase activity in renal transplant patients
30 f hepatic VLDL production as well as lowered lipoprotein lipase activity in serum compared with wild-
31 so associated with a substantial increase in lipoprotein lipase activity in the liver, which may have
32 n metabolism: liver-derived Angptl3 inhibits lipoprotein lipase activity primarily in the fed state,
34 density lipoproteins is not due to perturbed lipoprotein lipase activity, a major culprit of isolated
35 adds ApoC-I and ApoC-II, major modulators of lipoprotein lipase activity, and confirms previously dem
42 oxyacyl-CoA dehydrogenase (HADH) and adipose lipoprotein lipase (aLPL) activity, along with a decreas
43 ulin, adipocytes are known to secrete active lipoprotein lipase, an enzyme that binds to heparan sulf
45 bic signal sequence, and is 44% identical to lipoprotein lipase and 41% identical to hepatic lipase.
47 , both through the biochemical inhibition of lipoprotein lipase and by interfering with lipoprotein b
48 asma apoE, but neither significantly altered lipoprotein lipase and cholesteryl ester protein mass or
49 capillaries, and the fact that GPIHBP1 binds lipoprotein lipase and chylomicrons suggest that GPIHBP1
51 h the up-regulation of target genes, such as lipoprotein lipase and glutathione S-transferase alpha-2
52 ion of lipid detoxification enzymes, such as lipoprotein lipase and glutathione S-transferase alpha-2
55 cations, that Lmf1 interacts physically with lipoprotein lipase and hepatic lipase and localizes the
56 ring the levels and activity of key enzymes (lipoprotein lipase and hepatic lipase) responsible for t
57 other two major members of this gene family, lipoprotein lipase and hepatic lipase, and has implicati
58 Recent studies indicate that in addition to lipoprotein lipase and hepatic lipase, the maturation of
61 ow that intravascular lipolysis by adipocyte lipoprotein lipase and hepatic uptake of HDL by scavenge
63 the most compelling evidence revolves around lipoprotein lipase and its endogenous facilitator (APOA5
64 some 8 between D8S1130 and D8S1106, near the lipoprotein lipase and macrophage scavenger receptor gen
65 broad, we will focus on the roles played by lipoprotein lipase and proteoglycans in this process.
66 explained by increased expression of hepatic lipoprotein lipase and reduced expression of microsomal
67 Acute hepcidin administration down-regulated lipoprotein lipase and up-regulated Socs3 in visceral ad
68 bolism by increasing the gene expression for lipoprotein lipase and very-low-density lipoprotein rece
69 on and gene expression of bone sialoprotein, lipoprotein lipase, and fatty acid binding protein 4 are
70 lipolytic enzymes (hormone-sensitive lipase, lipoprotein lipase, and fatty acid binding protein 4) ve
72 the lipase gene family, hepatic lipase (HL), lipoprotein lipase, and pancreatic lipase, HL exhibits t
73 e-sensitive lipase, monoacylglycerol lipase, lipoprotein lipase, and patatin domain-containing phosph
75 synthase, as well as other adipogenic genes, lipoprotein lipase, and peroxisome proliferator-activate
76 he tissue with the most robust expression of lipoprotein lipase, and recent data attest to the import
77 inogen activator inhibitor type 1 complexes, lipoprotein lipase, and the 39-kDa receptor-associated p
78 rts of transgenic mice expressed the altered lipoprotein lipase, and the protein localized to the sur
79 ibits a key enzyme of lipoprotein clearance, lipoprotein lipase, and up-regulates a lipoprotein lipas
81 e physiological extracellular chaperones for lipoprotein lipase as it translocates from its site of s
83 ed a cell surface-associated beta-lactamase, lipoprotein, lipase, autolysin, and an ABC transporter l
85 an flies), a class of proteins homologous to lipoprotein lipases called yolk polypeptides (YP) are ac
86 p-nitrophenyl-alpha-glucopyranoside and the lipoprotein lipase-catalyzed ester hydrolysis of resoruf
87 -stimulated expression of the genes encoding lipoprotein lipase, CD36, LXR alpha, and ABCG1 in thiogl
88 encoding apo A-IV, apo B, apo C-III, apo E, lipoprotein lipase, cholesteryl ester transfer protein,
95 docrine or autocrine/paracarine inhibitor of lipoprotein lipase depending on its sites of expression.
96 urements, we have assessed the regulation of lipoprotein lipase-derived fatty acid entrapment in subc
99 Cs, in part, by driving endothelial CD36 and lipoprotein lipase expression and facilitate FA transpor
102 protein 1 (GPIHBP1), the molecule that moves lipoprotein lipase from the interstitial spaces to the c
103 .7 kb of genomic DNA sequence from the human lipoprotein lipase gene (LPL), scored in 71 individuals
105 is applied to data from a region within the lipoprotein lipase gene and the amount of detected recom
107 ear factor-3 site created in intron 8 of the lipoprotein lipase gene by a common single-nucleotide po
108 (EL) is a recently discovered member of the lipoprotein lipase gene family that hydrolyzes HDL phosp
109 of endothelial lipase (EL), a member of the lipoprotein lipase gene family, markedly reduces HDL-C l
110 se discovery rate [FDR], P<0.0001), an N291S lipoprotein lipase gene polymorphism (OR, 3.09; 95% CI,
114 e, subfamily A (ABC1), member 1 (ABCA1), and lipoprotein lipase genes predicted to be damaging were i
118 of a selected group of lipases that include lipoprotein lipase, hepatic lipase and endothelial lipas
120 iver and increased plasma enzyme activity of lipoprotein lipase, hepatic lipase, and phospholipid tra
121 ms within the genes for apoE, apoB, apoCIII, lipoprotein lipase, hepatic lipase, endothelial lipase,
122 ingle intramuscular (i.m.) injections, human lipoprotein lipase (hLPL) mRNA was detectable in the qua
123 of new molecules that affect the activity of lipoprotein lipase holds great potential for novel thera
128 he expression of the glucose transporter and lipoprotein lipase in peripheral tissues, which is respo
129 sue, in that all the fatty acids released by lipoprotein lipase in skeletal muscle are taken up by th
131 e proliferator-activated receptor-gamma2 and lipoprotein lipase) in human MSCs after 21 days of treat
132 PRE-bound PV on a PPARgamma-target gene, the lipoprotein lipase, in vivo, suggesting the dominant act
133 increase in adipose Angptl4 and the ensuing lipoprotein lipase inactivation may contribute to athero
135 ed adipose Angptl4 levels, inhibited adipose lipoprotein lipase, increased fasting levels of plasma t
136 mice was associated with fatty acid-mediated lipoprotein lipase inhibition and changes in a PPARgamma
137 POC-III in order to reduce the activation of lipoprotein lipase inhibition during hypertriglyceridemi
138 mice established that Fiaf is a circulating lipoprotein lipase inhibitor and that its suppression is
139 induced adipose factor (Fiaf), a circulating lipoprotein lipase inhibitor whose expression is normall
140 ance, lipoprotein lipase, and up-regulates a lipoprotein lipase inhibitor, angiopoietin-like 4 (Angpt
146 uced adipose factor), a protein inhibitor of lipoprotein lipase, is synthesized and secreted during f
149 nd E), enzymes involved in lipid processing (lipoprotein lipase, lecithin cholesteryl ester transfera
150 The effects of n-3 FA on modulating arterial lipoprotein lipase levels link to changes in lipid depos
153 f the cellular regulation of skeletal muscle lipoprotein lipase (LPL) (a protein important for contro
154 er in b/b than +/b rats due to reduced serum lipoprotein lipase (LPL) activity (3.1 vs. 5.0 mM/min; P
156 a significant increase of postheparin plasma lipoprotein lipase (LPL) activity compared with mice tha
161 roduction but suppresses post-heparin plasma lipoprotein lipase (LPL) activity suggesting that the hy
163 ins (apo) C-I and C-III are known to inhibit lipoprotein lipase (LPL) activity, but the molecular mec
164 d to be a key mediator of GIP stimulation of lipoprotein lipase (LPL) activity, involving activation
165 in-like 4 (ANGPTL4), a protein that inhibits lipoprotein lipase (LPL) activity, is highly expressed i
168 re deficient in adipose tissue expression of lipoprotein lipase (LpL) also have less fat, but only wh
170 t the genes with highest scores were: ABCA1, lipoprotein lipase (LPL) and cholesterol ester transfer
175 In this report, we show that RAP binds to lipoprotein lipase (LPL) and may play a role in the matu
176 de-rich lipoproteins to remnant particles by lipoprotein lipase (LPL) and their uptake by the liver.
177 GPI-anchored endothelial cell protein, binds lipoprotein lipase (LPL) and transports it into the lume
178 oprotein C-II (apoC-II) is the co-factor for lipoprotein lipase (LPL) at the surface of triacylglycer
179 the lymphocyte antigen 6 (Ly6) family, binds lipoprotein lipase (LPL) avidly and is required for the
181 (AAV-1)-mediated gene transfer to muscle for lipoprotein lipase (LPL) deficiency, 1 subject from the
183 cles hydrolyzed in vitro through addition of lipoprotein lipase (LpL) exhibit strikingly similar chan
186 ein of capillary endothelial cells, shuttles lipoprotein lipase (LPL) from subendothelial spaces to t
187 endothelial membrane protein that transports lipoprotein lipase (LPL) from the subendothelial space t
188 an endothelial cell protein that transports lipoprotein lipase (LPL) from the subendothelial spaces
189 that included human Chromosome 21, the human lipoprotein lipase (LPL) gene locus and the multi-locus
190 evant published datasets including the human lipoprotein lipase (LPL) gene locus, the human Y-chromos
191 .7 kb of genomic DNA sequence from the human lipoprotein lipase (LPL) gene was scored in three popula
193 otein-TAG may gain access to target cells by lipoprotein lipase (LPL) hydrolysis or via receptor-medi
196 ectin (Adipoq) promoter drives expression of lipoprotein lipase (LPL) in adipocytes to potentially in
197 ol, we investigated whether lipid uptake via lipoprotein lipase (LPL) in astrocytes is required to ce
199 nd found that mRNA and protein expression of lipoprotein lipase (LPL) in skeletal muscle was signific
209 ncreased risk of cardiovascular disease, and lipoprotein lipase (LPL) is the rate-limiting enzyme for
210 ptake, and gene expression in heart-specific lipoprotein lipase (LpL) knock-out (hLpL0), CD36 knock-o
211 ass B type I levels but paralleled increased lipoprotein lipase (LPL) levels and LPL distribution in
212 lipolytic products produced by the action of lipoprotein lipase (LPL) on circulating triglyceride-ric
213 tty acids derived from the action of cardiac lipoprotein lipase (LPL) on plasma lipoproteins may cont
219 showed that modification of HCV particles by lipoprotein lipase (LPL) reduces HCV infectivity and inc
221 exposing LDL(-) to the key lipolytic enzyme lipoprotein lipase (LPL) reversed these responses, inhib
222 of plasma triglyceride metabolism, binds to lipoprotein lipase (LPL) through its N-terminal coiled-c
223 gress on GPIHBP1, a molecule that transports lipoprotein lipase (LPL) to the capillary lumen, and dis
226 PPARgamma coactivator 1beta (PGC1beta), and lipoprotein lipase (LPL) were among the up-regulated gen
227 Transgenic mice expressing non-transferable lipoprotein lipase (LpL) with a glycosylated phosphatidy
228 in of capillary endothelial cells that binds lipoprotein lipase (LPL) within the interstitial space a
229 in of microvascular endothelial cells, binds lipoprotein lipase (LPL) within the interstitial spaces
230 and validate candidate functional SNPs using lipoprotein lipase (LPL), a gene previously associated w
231 A well-known cause is the deficiency of lipoprotein lipase (LPL), a key enzyme in plasma triglyc
232 (betaLPL-TG) or inactivation (betaLPL-KO) of lipoprotein lipase (LPL), a physiologic provider of fatt
233 It is known as an endogenous inhibitor of lipoprotein lipase (LPL), and it modulates lipid deposit
234 icron-sized n-6 TG emulsions is modulated by lipoprotein lipase (LPL), apoE, LDL-R, and lactoferrin-s
235 e metabolism, fatty acid synthase (FAS), and lipoprotein lipase (LPL), as well as on circulating leve
236 adipocyte fatty acid-binding protein (aP2), lipoprotein lipase (LPL), fatty acid synthase (FAS), hor
237 a (PPARgamma), leptin, adiponectin, adipsin, lipoprotein lipase (LPL), Glut 1, Glut 3, but not Glut 4
238 treatment lowered plasma TGs in mice lacking lipoprotein lipase (LPL), hepatic heparan sulfate proteo
241 physiologically important proteins, such as lipoprotein lipase (LPL), leptin, adipsin, Acrp30, etc.
242 y acids and SNPs in apolipoprotein J (APOJ), lipoprotein lipase (LPL), macrophage scavenger receptor
243 fficient triglyceride clearance catalyzed by lipoprotein lipase (Lpl), partly due to defective expres
244 ssion of glucose transporter type 4 (GLUT4), lipoprotein lipase (LpL), peroxisome proliferator-activa
247 didate gene that emerged from our screen was lipoprotein lipase (Lpl), which encodes an enzyme that f
248 cids associated with albumin or derived from lipoprotein lipase (LpL)-mediated hydrolysis of lipoprot
249 lting in hypertriglyceridemia, by inhibiting lipoprotein lipase (LPL)-mediated hydrolysis of plasma t
265 effects on plasma lipolytic activity through lipoprotein lipase-mediated clearance, as well as stimul
266 iglyceride-derived fatty acids, generated by lipoprotein lipase-mediated hydrolysis of triglycerides,
267 CD36 expression in macrophage, inhibition of lipoprotein lipase-mediated lipolysis, decreased adipone
269 giopoietin-like 4 (ANGPTL4), an inhibitor of lipoprotein lipase-mediated plasma triglyceride clearanc
270 gptl4 is a secreted protein and inhibitor of lipoprotein lipase-mediated plasma triglyceride clearanc
273 sin heavy-chain promoter upstream of a human lipoprotein lipase minigene construct with a glycosylpho
274 different lipoprotein lipase variants, each lipoprotein lipase mutant allele was considered separate
277 ylation of the zeta-associated protein gene, lipoprotein lipase overexpression, telomere length, and
278 ugh the lepidopteran ESP/YP2s are related to lipoprotein lipases, previous attempts to directly demon
279 SUV39H1 to the PPAR response element of the lipoprotein lipase promoter and decreased acetylation of
280 ted receptor gamma-responsive element of the lipoprotein lipase promoter in the context of the local
281 te morphology or in the expression levels of lipoprotein lipase, proxisomal proliferation-activating
282 Lipid droplet formation was reduced when lipoprotein lipase-released fatty acids were bound by BS
283 of the "regulatory module" with the "lid" of lipoprotein lipase resulted in enzymatically inactive pr
284 arterial wall that promote retention such as lipoprotein lipase, secretory sphingomyelinase, and secr
285 eted disruption of the TG-hydrolyzing enzyme lipoprotein lipase specifically in the nucleus accumbens
286 low HDL-C syndromes in humans include APOC3, lipoprotein lipase, sphingomyelin phosphodiesterase 1, a
287 stigate the role of Angptl4, an inhibitor of lipoprotein lipase that is induced by >3-fold in the hea
288 t the higher dipterans did not requisition a lipoprotein lipase to replace Vg as a yolk protein precu
290 differing effects associated with different lipoprotein lipase variants, each lipoprotein lipase mut
292 or-activated receptor gamma (PPARgamma), and lipoprotein lipase was elevated in LGD1069-responding tu
293 eling for carboxymethyllysine, biglycan, and lipoprotein lipase was found in D-galactose-treated mice
295 t P. gingivalis bacterial cells treated with lipoprotein lipase were attenuated in their ability to a
296 The fed/fasted activities of adipose tissue lipoprotein lipase were not significantly different betw
297 muscle- and liver-specific overexpression of lipoprotein lipase were studied during a 2-h hyperinsuli
298 mice with an adenovirus-expressing wild-type lipoprotein lipase, whereas an inactive lipoprotein lipa
299 c-Myc cooperated to induce the expression of lipoprotein lipase, which was required for proliferation
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。